Johnson & Johnson plans to deliver 20 million doses of its COVID-19 vaccine candidate to the United States by the end of March if the Food and Drug Administration authorizes emergency use of the single-dose vaccine, a company executive told a House subcommittee today at a hearing on expanding vaccine availability.

An FDA advisory committee expects Friday to consider the emergency use application. If authorized for emergency use, the J&J candidate would be the third COVID-19 vaccine authorized for use in the United States, joining the Pfizer and Moderna vaccines. The departments of Health and Human Services and Defense in August agreed to purchase 100 million doses of the J&J vaccine candidate and could acquire up to 300 million additional doses under the agreement.

Related News Articles

Headline
A recent report from RAND “misses the mark on solutions to the cost of health care and draws its conclusions from the same recycled and incomplete studies,”…
Headline
Mask mandates last year were associated with declining growth in daily COVID-19 cases and deaths within 20 days, while on-premises restaurant dining was…
Headline
The Centers for Disease Control and Prevention will host a March 11 call for clinicians on using telehealth to augment COVID-19 vaccine planning and monitoring…
Perspective
1.5 million people. That’s the approximate number of people that hospitals and health systems have treated for COVID-19 since the pandemic began. To put that…
Blog
A recent report from RAND misses the mark on solutions to the cost of health care and draws its conclusions from the same recycled and incomplete studies.…
Headline
A research letter published yesterday in the New England Journal of Medicine looks at delayed injection-site skin reactions to the Moderna COVID-19 vaccine…